Akums Drugs and Pharmaceuticals Ltd
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India''s Manufacturing Business
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 23 Jul 2026, 11:19 PM IST · BSE ID: 7cc2b74c-8588-4b4f-986f-c30fa49ef85c
View Original BSE Filing (PDF)
💡
In Simple Terms
Akums Drugs bought Oriflame India's factories and a warehouse for INR 56 Crore to expand into cosmetics.
🤖 AI Summary
- Akums Drugs' wholly-owned subsidiary acquired Oriflame India's manufacturing business for INR 56 Crore.
- The acquisition includes two manufacturing plants located at Roorkee, Uttarakhand and Noida, Uttar Pradesh.
- A leased warehouse situated at Noida is also part of the manufacturing business acquisition.
- The transaction enables Akums' entry into color cosmetics and expands its skincare and wellness product presence.
- The acquisition is expected to be completed by August 31, 2026, and involves cash consideration.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Consideration
INR 56 Crore
🏢 How This Affects the Company
This acquisition marks Akums' entry into the color cosmetics segment, expanding its product portfolio beyond existing offerings. It also enhances its presence in the skincare and wellness products market.
The acquisition involves a cash consideration of INR 56 Crore, which will impact the company's cash reserves or debt levels. Specific details on funding sources are not disclosed.
Akums will gain two manufacturing plants in Roorkee and Noida, along with a leased warehouse, increasing its overall manufacturing capacity and capability for cosmetic and wellness products.
No prior governmental or regulatory approvals are required for this transaction, which streamlines the acquisition process. The filing does not introduce new specific risks.
👥 What This Means For Shareholders
✅
Action Required
No action is required by shareholders based on this intimation.
👤
Who Is Affected
Shareholders of Akums Drugs and Pharmaceuticals are affected by the company's strategic decision to expand into a new business segment and commit INR 56 Crore for this acquisition.
🔍
Management Signal
The decision indicates management's intent to diversify its business lines and leverage manufacturing capabilities to enter new, growing market segments like cosmetics.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Completion of the acquisition by August 31, 2026.
Details on how the INR 56 Crore consideration is financed.
Updates on the integration of the new manufacturing facilities.
LOW RISK
The filing reports a strategic acquisition without immediate identified risks or regulatory hurdles.
💡 Investor Takeaway
Akums Drugs and Pharmaceuticals, through its subsidiary, is acquiring Oriflame India’s manufacturing business for INR 56 Crore cash consideration. This includes two manufacturing plants and a leased warehouse, establishing Akums' entry into color cosmetics and expanding its skincare/wellness portfolio.
⚖️ Strengths & Concerns
✅ Positives
- Entry into the fast-growing cosmetics sector, specifically color cosmetics, diversifying Akums' product lines.
- Expansion of manufacturing capacity with two established plants and a leased warehouse, enhancing operational scale.
📅 Company Track Record
No previous filings were found for Akums Drugs and Pharmaceuticals Ltd. The company was incorporated on November 1, 2023, and listed on BSE on June 27, 2024. Therefore, limited public track record is available.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What business is Akums Drugs and Pharmaceuticals acquiring?
Akums Drugs and Pharmaceuticals, through its subsidiary, is acquiring Oriflame India Private Limited's manufacturing business, which includes two manufacturing plants and a leased warehouse.
What is the total cost of Akums Drugs' acquisition of Oriflame India's manufacturing business?
The total consideration for the acquisition of Oriflame India's manufacturing business is INR 56 Crore.
What is the expected completion timeline for Akums Drugs' acquisition?
The acquisition of Oriflame India's manufacturing business is expected to be completed by August 31, 2026.
What products will Akums Drugs expand into with this acquisition?
This acquisition marks Akums' entry into color cosmetics and expands its presence in skincare and wellness products.
Are Oriflame's trademarks part of this acquisition?
No, the trademark and marketing of Oriflame’s products in India are not part of this transaction.
Questions based on this BSE filing only. For information purposes.